Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

International Clinical Psychopharmacology

Volumn 18, Issue 6, 2003, Pages 305-313

  Silver, Henry ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Sha'ar Menashe MHC   (Israel)

Author keywords

Drug drug interactions; Fluvoxamine; Negative symptoms; Pharmacokinetics; Schizophrenia; SSRI

Indexed keywords

CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MAPROTILINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

BRADYKINESIA; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL PATIENT; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RATING SCALE; REVIEW; SIDE EFFECT; SYMPTOM;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN UPTAKE INHIBITORS;

EID: 0842287699     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200311000-00001     Document Type: Review

References (103)

1. Addington D, Addington J, Schissel B (1990). A depression rating scale for schizophrenics. Schizophr Res 3:247-251.
2. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201-208.
3. Addington D, Addington J, Atkinson M (1996). A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 19:205-212.
4. Addington D, Addington J, Patten S (1998). Depression in people with first-episode schizophrenia. Br J Psychiatry 172 (Suppl 33):90-92.
5. Alphs LD, Summerfelt A, Lann H, Muller RJ (1989). The negative symptoms assessment: a new instrument to assess negative symptoms of schizoprhenia. Psychopharmacol Bull 25:159-163.
6. Andreasen NC (1982). Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:789-794.
7. Andreasen NC (1983). Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
8. Andreasen NC (1984). Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
9. Andreasen NC, Olsen S (1982). Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 39:789-794.
10. Andreasen NC, Flaum M, Swayze VW II, Tyrrell G, Arndt S (1990). Positive and negative symptoms in schizophrenia a critical reappraisal. Arch Gen Psychiatry 47:615-621.
11. Arango C, Kirkpatrick B, Buchanan, RW (2000). Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis 188:50-53.
12. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P (1995). A longitudinal study of symptom dimentsions in schizophrenia: prediction and patterns of change. Arch Gen Psychiatry 52:352-360.
13. Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, et al. (1997). Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 35:335-339.
14. Barnes TR, Curson DA, Liddle PF, Patel M (1989). The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 154: 486-491.
15. Baynes D, Mulholland C, Cooper SJ, Montgomery RC, MacFlynn G, Lynch G, et al. (2000). Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 45:47-56.
16. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A (1996). Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153:1625-1627.
17. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999). Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193.
18. Carpenter WT Jr, Kirkpatrick B (1988). The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 14:645-652.
19. Carpenter WT, Heinrichs DW, Alphs LD (1985). Treatment of negative symptoms. Schizophr Bull 11:440-452.
20. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG (1996). Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153:820-822.
21. Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, Jann MW (1999). In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) 145:91-98.
22. Chong SA, Tan CH, Lee HS (1997). Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports [letter]. J Clin Psychopharmacol 17:68-69.
23. Collins AA, Remington G, Coulter K, Birkett K (1996). Depression in schizophrenia: a comparison of three measures. Schizophr Res 20:205-209.
24. Crow TJ (1980). Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137:383-386.
25. Czobor P, Bitter I, Volavka J (1990). Relationship between the Brief Psychiatric Rating Scale and the Scale for Assessment of Negative Symptoms: a study of the correlation and redundancy. Psychiatry Res 36:129-139.
26. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, et al. (1994). Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14:340-343.
27. Edwards J, McGorry PD, Waddell FM, Harrigan SM (1999). Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. Schizophr Res 40:147-158.
28. El Yazaji M, Battas O, Agoub M, Moussaoui D, Gutknecht C, Dalery J, et al. (2002). Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. Schizophr Res 56:121-127.
29. Evins AE, Goff DC (1996). Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 2:130-147.
30. Fenton WS, McGlashan TH (1992). Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 49:179-184.
31. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF (1998). A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 43:1082-1085.
32. Galynker I, Prikhojan A, Phillips E, Focseneanu M, Ieronimo C, Rosenthal R (1997). Negative symptoms in stroke patients and length of hospital stay. J Nerv Ment Dis 185:616-621.
33. Galynker II, Cohen LJ, Cai J (2000). Negative symptoms in patients with major depressive disorder: a preliminary report. Neuropsychiatry Neuropsychol Behav Neurol 13:171-176.
34. Garver DL, Holcomb JA, Christensen JD (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J Clin Psychiatry 61:964-972.
35. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E (1995). A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 117:417-423.
36. Hamilton M (1970). The classification of depressive illness. Br J Psychiatry 117:348-349.
37. Harvey PD, Putman KM, Davidson M, Kahn RS, Powchik P, McQueeney R, et al. (1991). Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res 38:285-292.
38. Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS, Weinberger DR (1988). Psychomotor slowing, negative symptoms and dopamine receptor availability - an IBZM SPECTstudy in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res 31:19-26.
39. Herbener ES, Harrow M (2001). Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients. Schizophr Bull 27:527-537.
40. Hernandez L, Baptista T, Hoebel BG (1990). Neurochemical effects of chronic haloperidol and lithium assessed by brain microdialysis in rats. Prog Neuropsychopharmacol Biol Psychiatry 14 (suppl):S17-S35.
41. Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Hartter S, et al. (2002). Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22: 502-506.
42. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T (2000). Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 149:163-169.
43. Hirsch SR, Jolley AG, Barnes TR, Liddle PF, Curson DA, Patel A, et al. (1989). Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res 2:259-264.
44. Iager A, Kirsch D, Wyatt R (1986). A negative symptom rating scale. Psychiatry Res 16:27-36.
45. Invernizzi R, Pozzi L, Samanin R (1995). Further studies on the effects of chronic clozapine on regional extracellular dopamine levels in the brain of conscious rats. Brain Res 670:165-168.
46. Kane JM, Woerner M, Sarantakos S (1986). Depot neuroleptics: a comparative review of standard, intermediate, and low dose regimen. J Clin Psychiatry 47 (suppl 5):S30-S33.
47. Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV (2001). Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Ger Psychiatry 16:1163-1167.
48. Kay SR, Opler LA, Lindenmayer JP (1987). Reliability and validity of the positive and negative syndrome scale for schizoprhenics. Psychiatry Res 23:99-110.
49. Kelley ME, van Kammen DP, Allen DN (1999). Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry 156:406-411.
50. Kirkpatrick B, Buchanan R, McKenney P (1989). The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119-123.
51. Kuck J, Zisook S, Moranville JT, Heaton RK, Braff DL (1992). Negative symptomatology in schizophrenic outpatients. J Nerv Ment Dis 180: 510-515.
52. Kulhara P, Avasthi A, Chadda R, Chandiramani K, Mattoo SK, Kota SK, Joseph S (1989). Negative and depressive symptoms in schizophrenia. Br J Psychiatry 154:207-211.
53. Lammers CH, Deuschle M, Weigmann H, Hartter S, Hiemke C, Heese C, Heuser I (1999). Coadministration of clozapine and fluvoxamine in psychotic patients-clinical experience. Pharmacopsychiatry 32:76-77.
54. Lee MS, Kim YK, Lee SK, Suh KY (1998). A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 18:399-403.
55. Li XM, Perry KW, Wong DT, Bymaster FP (1998). Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 136:153-161.
56. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH (2000). Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 61:594-599.
57. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PR (1984). Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41:1025-1029.
58. Melis M, Diana M, Gessa GL (1999). Clozapine potently stimulates mesocortical dopamine neurons. Eur J Pharmacol 366:R11-R13.
59. Meltzer HY (1992). The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 160 (suppl 17):22-29.
60. Moller H (1995). The negative component in schizophrenia. Acta Psychiatr Scand 91:11-14.
61. Moller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, et al. (1994). Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology (Berl) 115:221-228.
62. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
63. Mortimer AM, Lund CE, McKenna PJ (1990). The positive negative dichotomy in schizophrenia. Br J Psychiatry 157:41-49.
64. Newcomer JW, Faustman WO, Yeh W, Csernansky JG (1990). Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res 31:243-250.
65. Overall JE, Gorham DR (1962). The brief psychiatric rating scale (BPRS). Psychol Rep 10:799-812.
66. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF (2000). Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 157:1461-1466.
67. Pogue-Geile MF, Harrow M (1984). Negative and positive symptoms in schizophrenia and depression: a follow-up. Schizophr Bull 10:371-387.
68. Poyurovsky M, Isakov V, Hromnikov S, Modai I, Rauchberger B, Schneidman M, Weizman A (1999). Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol 14:95-100.
69. Remington G, Chong SA, Kapur S (1999). Distinguishing change in primary and secondary negative symptoms. Am J Psychiatry 156:974-975.
70. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000). 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237.
71. Salokangas RK, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, et al. (1996). Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatrica Scand 94:175-180.
72. Selten JP, Gernaat HB, Nolen WA, Wiersma D, van den Bosch RJ (1998). Experience of negative symptoms: comparison of schizophrenic patients to patients with a depressive disorder and to normal subjects. Am J Psychiatry 155:350-354.
73. Silver H (2001). Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283-304.
74. Silver H, Lerer B (1995). Psychopathological dimensions in schizophrenia. In: Ben Shachar G, Lieblich A (editors): Studies in Psychology. Festschrift in Honour of S. Kugelmass. Jerusalem: Magnes Press The Hebrew University.
75. Silver H, Nassar A (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add on double blind placebo controlled study. Biol Psychiatry 31:698-704.
76. Silver H, Shmugliakov N (1998). Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. J Clin Psychopharmacol 18:208-211.
77. Silver H, Jahjah N, Kushnir M (1995a). Psychotic symptoms in schizophrenics during chronic fluvoxamine treatment. A report of two cases. Schizophr Res 16:77-79.
78. Silver H, Kaplan A, Kushnir M (1995b). Fluvoxamine augmentation in chronic schizophrenia. An open exploratory study. Hum Psychopharmacol 10:59-63.
79. Silver H, Kaplan A, Jahjah, N (1995c). Fluvoxamine augmentation in clozapine resistant schizophrenia. Am J Psychiatry 152:1098.
80. Silver H, Kushnir M, Kaplan A (1996). Fluvoxamine augmentation in clozapine resistant schizophrenia. An open pilot study. Biol Psychiatry 40:671-674.
81. Silver H, Barash I, Aharon N, Kaplan A, PoyurovskyM (2000). Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 15:257-261.
82. Silver H, Aharon N, Kaplan A (2003a). Add on fluvoxamine improves primary negative symptoms. Evidence for specificity from response analysis of individual symptoms. Schizophr Bull, in press.
83. Silver H, Nassar A, Aharon N, Kaplan A (2003b). The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 18:87-92.
84. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
85. Siris S (1991). Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 17:75-97.
86. Siris SG (1993). Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 163(suppl 22):66-78.
87. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988). Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 145:1532-1537.
88. Sommers A (1985). 'Negative symptoms': conceptual and methodological problems. Schizophr Bull 11:364-379.
89. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, et al. (1994). Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 9:281-285.
90. Spina E, Avenoso A, Facciola G, Fabrazzo M, Monteleone P, Maj M, et al. (1998). Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 13:141-145.
91. Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M, Madia A (2000). Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 33:213-217.
92. Szegedi A, Wiesner J, Hiemke C (1995). Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 15:141-143.
93. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, et al. (1999). Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148-153.
94. Takashi H, Sugita T, Higuchi H, Shimizu T (2002). Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol 17:95-98.
95. Thiemann S, Csernansky J, Berger P (1987). Rating scales in research: the case of negative symptoms. Psychiatry Res 20:47-55.
96. Van Putten T, May RP (1978). 'Akinetic depression' in schizophrenia. Arch Gen Psychiatry 35:1101-1107.
97. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669.
98. Weinberger DR, Berman KF (1996). Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci 29:1495-1503.
99. Welham J, Stedman T, Clair A (1999). Choosing negative symptom instruments: issues of representation and redundancy. Psychiatry Res 30:47-56.
100. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Harter S, Hiemke C (1998). Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18:2-9.
101. Yadid G, Pacak K, Kopin IJ, Goldstein DS (1994). Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Therapeut 270:1158-1165.
102. Zhang W, Perry KW, Wong DT (2000). Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250-262.
103. Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, et al. (1999). Depressive symptoms in schizophrenia. Am J Psychiatry 156:1736-1743.